Page 30 - Read Online
P. 30

Page 8 of 9                                                   Mehta et al. Hepatoma Res 2018;4:7  I  http://dx.doi.org/10.20517/2394-5079.2017.35


               Financial support and sponsorship
               None.


               Conflicts of interest
               There are no conflicts of interest.

               Patient consent
               Patients consent could not be obtained.

               Ethics approval
               While IRB approval at our institution is not required for a solitary case presentation, the data is collect as
               part of an IRB approved prospective database through Interventional Radiology.


               Copyright
               © The Author(s) 2018.



               REFERENCES
               1.   Mistinova J, Valacsai F, Varga I. Congenital absence of the portal vein - case report and a review of literature. Clin Anat 2010;23:750-8.
               2.   Marks C. Developmental basis of the portal venous system. Am J Surg 1969;117:671-81.
               3.   Abernethy J. Account of two instances of uncommon formation in the viscera of the human body. Phil Trans R Soc Lond B Biol Sci
                   1793;83:295-9.
               4.   Hao Y, Hong X, Zhao X. Congenital absence of the portal vein associated with focal nodular hyperplasia of the liver and congenital heart
                   disease: a case report and literature review. Oncol Lett 2015;9:695-700.
               5.   Morgan G, Superina R. Congenital absence of the portal vein: two cases and a proposed classification system for portosystemic vascular
                   anomalies. J Pediatr Surg 1994;29:1239-41.
               6.   Cholongitas E, Papatheodoridis GV, Vangeli M, Terreni N, Patch D, Burroughs AK. Systematic review: the model for end-stage liver
                   disease--should it replace Child-Pugh’s classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther 2005;22:1079-89.
               7.   Lencioni R. Chemoembolization for hepatocellular carcinoma. Semin Oncol 2012;39:503-9.
               8.   Starzl TE, Francavilla A, Halgrimson CG, Francavilla FR, Porter KA, Brown TH, Putnam CW. The origin, hormonal nature, and action of
                   hepatotrophic substances in portal venous blood. Surg Gynecol Obstet 1973;137:179-99.
               9.   Kamiya S, Taniguchi I, Yamamoto T, Sawamura S, Kai M, Ohnishi N, Tsuda M, Yamamura M, Nakasaki H, Yokoyama S. Analysis of
                   intestinal flora of a patient with congenital absence of the portal vein. FEMS Immunol Med Microbiol 1993;7:73-80.
               10.  Lundstedt C, Lindell G, Tranberg KG, Svartholm E. Congenital absence of the intrahepatic portion of the portal vein in an adult male
                   resected for hepatocellular carcinoma. Eur Radiol 2001;11:2228-31.
               11.  Morotti RA, Killackey M, Shneider BL, Repucci A, Emre S, Thung SN. Hepatocellular carcinoma and congenital absence of the portal
                   vein in a child receiving growth hormone therapy for turner syndrome. Semin Liver Dis 2007;27:427-31.
               12.  Pichon N, Maisonnette F, Pichon-Lefievre F, Valleix D, Pillegand B. Hepatocarcinoma with congenital agenesis of the portal vein. Jpn J
                   Clin Oncol 2003;33:314-6.
               13.  Hu GH, Shen LG, Yang J, Mei JH, Zhu YF. Insight into congenital absence of the portal vein: is it rare? World J Gastroenterol
                   2008;14:5969-79.
               14.  Reynolds AR, Furlan A, Fetzer DT, Sasatomi E, Borhani AA, Heller MT, Tublin ME. Infiltrative hepatocellular carcinoma: what
                   radiologists need to know. Radiographics 2015;35:371-86.
               15.  Thian YL, Low AS, Chow PK, Ooi LL, Chung AY, Low SC, Xie W, Thng CH. Atypical enhancement pattern of hepatocellular carcinoma
                   with portal vein thrombosis on multiphasic CT. Ann Acad Med Singapore 2011;40:454-9.
               16.  Lam A, Fernando D, Sirlin CC, Nayyar M, Goodwin SC, Imagawa DK, Lall C. Value of the portal venous phase in evaluation of treated
                   hepatocellular carcinoma following transcatheter arterial chemoembolisation. Clin Radiol 2017;72:994.e9-16.
               17.  Furlan A, Marin D, Vanzulli A, Patera GP, Ronzoni A, Midiri M, Bazzocchi M, Lagalla R, Brancatelli G. Hepatocellular carcinoma
                   in cirrhotic patients at multidetector CT: hepatic venous phase versus delayed phase for the detection of tumour washout. Br J Radiol
                   2011;84:403-12.
               18.  Monzawa S, Ichikawa T, Nakajima H, Kitanaka Y, Omata K, Araki T. Dynamic CT for detecting small hepatocellular carcinoma:
                   usefulness of delayed phase imaging. AJR Am J Roentgenol 2007;188:147-53.
               19.  López-Larramona G, Lucendo AJ, González-Castillo S, Tenias JM. Hepatic osteodystrophy: an important matter for consideration in
                   chronic liver disease. World J Hepatol 2011;3:300-7.
               20.  Lange PA, Stoller JK. The hepatopulmonary syndrome: effect of liver transplantation. Clin Chest Med 1996;17:115-23.
               21.  Lau WY, Sangro B, Chen PJ, Cheng SQ, Chow P, Lee RC, Leung T, Han KH, Poon RT. Treatment for hepatocellular carcinoma with
                   portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology 2013;84:311-8.
               22.  Joskin J, de Baere T, Auperin A, Tselikas L, Guiu B, Farouil G, Boige V, Malka D, Leboulleux S, Ducreux M, Baudin E, Deschamps
                   F. Predisposing factors of liver necrosis after transcatheter arterial chemoembolization in liver metastases from neuroendocrine tumor.
   25   26   27   28   29   30   31   32   33   34   35